LUND, Sweden, Sept. 14, 2021 /PRNewswire/ -- Immunovia AB
(publ) ("Immunovia"), a diagnostic company that develops and sells
highly accurate blood tests for the early detection of cancer,
today announced that the largest patient organization for
pancreatic cancer in the US – Pancreatic Cancer Action Network
(PanCAN) – informed their constituents about Immunovia, Inc.'s
blood test IMMray™ PanCan-d on its website, in social media and
through direct email contact.
PanCAN underlines that IMMray™ PanCan-d is the first-ever
blood test specific for pancreatic cancer and is available to
people considered at high risk for the disease, due to family
history or genetic alterations. PanCAN describes that the test is
requested through one's doctor, who also will receive the test
results from Immunovia, Inc. Interested individuals can contact
PanCAN Patient Services, which provides free information and
answers questions about the IMMray™ PanCan-d test.
"Pancreatic cancer is a tough disease. There isn't an early
detection test for the general population, and there are very few
treatment options, so it's exciting to see progress being made. The
Immunovia IMMray™ PanCan-d test is an important step for some
patients to be diagnosed earlier, have more treatment options and
live longer", said Julie
Fleshman, JD, MBA, President and CEO of Pancreatic Cancer
Action Network (PanCAN).
"It's of tremendous value that PanCAN helps to raise awareness
about Immunovia, Inc.'s blood test IMMray™ PanCan-d in the US.
PanCAN reaches a very wide audience and speaks directly to persons
in the familial/hereditary risk group that need to be given the
opportunity to get tested", said Patrik
Dahlen, Immunovia's CEO.
IMMray™ PanCan-d was launched by Immunovia, Inc. in the US in
August and is currently available in all states except from
New York, California, Maryland, Pennsylvania and Rhode Island.
For more information, please contact:
Patrik Dahlen, CEO
Tel: +46 73 376 76 64
Immunovia AB is a diagnostic company that is developing and
commercializing highly accurate blood tests for the early detection
of cancer and autoimmune diseases based on Immunovia's
proprietary test platform called IMMray™. Tests are based on
antibody biomarker microarray analysis using advanced
machine-learning and bioinformatics to single-out a set of relevant
biomarkers that indicate a certain disease. Thus, forming a unique
"disease biomarker signature".
The company was founded in 2007, based on cancer studies and
ground-breaking research in the Department of Immuntechnology at
Lund University and CREATE Health
Cancer Center, Sweden.
The first product, IMMray™ PanCan-d, is undergoing clinical
evaluation in some of the world's largest clinical studies for
high risk groups in pancreatic cancer, PanFAM-1, PanSYM-1 and
In 2017, Immunovia, Inc. was established in Marlborough, Massachusetts, USA. The IMMray™
PanCan-d test, the first blood-based test dedicated to the early
detection of pancreatic cancer on the market, is offered as a
laboratory developed test (LDT) exclusively through Immunovia, Inc.
For more information see: www.immunoviainc.com. The European
launch plan will be communicated during the second half of
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com.
This information was brought to you by Cision
The following files are available for download:
SOURCE Immunovia AB